

## Ogsievo(nirogacestat) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		_ MEMBER'S FIRST NAME:			
important for the review (	ut all applicable sections complee.g., chart notes or lab data, to lth Information under HIPAA.		•		
MEMBER INFORMATION	N				
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:		
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE ID	NUMBER:				
☐ MALE ☐ FEMALE I	HEIGHT (IN/CM): WE	IGHT (LB/KG):	ALLERGIES:		
FOLLOWING LINK: <u>HTTPS://MAGELLAN</u>	RESCRIBER, YOU WILL NEED TO SUBMIT A PHI D RX.COM/MEMBER/EXTERNAL/COMMERCIAL/G REPRESENTATIVE (IF APPLICABI	COMMON/DOC/EN-US/PHI DISC	LOSURE AUTHORIZATION.PDF		
AUTHORIZED REPRESENT	ATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMAT	ION				
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:		- 1			
CITY:		STATE:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT	OFFICE CONTACT PERSON:		
		•			
MEDICATION OR MEDIC	CAL DISPENSING INFORMATION	ON			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILL	QUANT S:	ITY:	
NEW THERAPY DURATION OF THERAPY	RENEWAL (SPECIFIC DATES):	IF RENEWAL: DA	TE THERAPY INITIATI	ED:	

Continued on next page





## Ogsievo(nirogacestat) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
□ Desmoid Tumor			
□ Other diagnosis:	ICD-10 Code(s):		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLIN	ICAL INFORMATION TO SUPPORT A	
Is patient going to be using drug in a	clinical trial? ☐ Yes ☐ No		
risk of significant morbidity?   Does patient have recurrent, measure Please submit documentation.  Does patient have refractory, measure Please submit documentation.	urably progressing DT/AF that is deemed No Please submit documentation.  rably progressing DT/AF following at lessent progressing DT/AF following DT/AF following at lessent progressing DT/AF following D	ast one line of therapy?	
Are there any other comments, diagnostician feels is important to this re	oses, symptoms, medications tried or fa	iled, and/or any other information the	
information is received.  ATTESTATION: I attest the information the Health Plan, insurer, Medical Grounds	re covered on all plans. This request may on provided is true and accurate to the bo up or its designees may perform a routing	est of my knowledge. I understand that e audit and request the medical	
information necessary to verify the ac	curacy of the information reported on th	is form.	
Prescriber Signature or Electronic I.D.	Verification:	Date:	
you are not the intended recipient, you are her	ompanying this transmission contain confidential reby notified that any disclosure, copying, distribu have received this information in error, please nese documents.	tion, or action taken in re liance on the contents	





## Ogsievo(nirogacestat) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn:CP-4201

P.O.Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

